PE20181894A1 - Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5 - Google Patents
Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5Info
- Publication number
- PE20181894A1 PE20181894A1 PE2018001785A PE2018001785A PE20181894A1 PE 20181894 A1 PE20181894 A1 PE 20181894A1 PE 2018001785 A PE2018001785 A PE 2018001785A PE 2018001785 A PE2018001785 A PE 2018001785A PE 20181894 A1 PE20181894 A1 PE 20181894A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halo
- new
- inhibitors
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- VZQXUWKZDSEQRR-UHFFFAOYSA-N Nucleosid Natural products C12=NC(SC)=NC(NCC=C(C)C)=C2N=CN1C1OC(CO)C(O)C1O VZQXUWKZDSEQRR-UHFFFAOYSA-N 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 101000924530 Homo sapiens Protein arginine N-methyltransferase 5 Proteins 0.000 abstract 2
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Referido a analogos de nucleosidos sustituidos de formula (I); en donde R1 es H o CH3; R2 es H; Ra y Rb son, independientemente, H o -C(=0)-alquiloC1-4; Y es -O-, -CH2- o -CF2-; R7a es H; R7b es H, o alquilo C1-4 opcionalmente sustituido con uno o mas atomos halo; X1 es un enlace covalente o -O-; X2 es un enlace covalente, -CH2-, -CF2-, entre otros; X3 es N o CH; R8 y R10 se selecciona independientemente entre H, halo, y alquiloC1-6 opcionalmente sustituido; R9 y R11 se selecciona independientemente entre halo, -NH2, entre otros; Z es -CH2-, -C(=O)-, entre otros; y Het es un sistema anular heterociclico aromatico biciclico seleccionado entre (a-1), (a-2), (a-3) y (a-4). Dichos compuestos son inhibidores de PRMT5 (proteina arginina metil transferasa 5). Tambien se refiere a composiciones farmaceuticas que comprenden dichos compuestos, asi como su uso en el tratamiento o prevencion de enfermedades como trastorno metabolico, trastorno autoinmunitario, cancer, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306222P | 2016-03-10 | 2016-03-10 | |
| EP16162731 | 2016-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181894A1 true PE20181894A1 (es) | 2018-12-11 |
Family
ID=55640627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001785A PE20181894A1 (es) | 2016-03-10 | 2017-02-24 | Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3426664B1 (es) |
| KR (1) | KR20180116307A (es) |
| CN (1) | CN108884108B (es) |
| AU (1) | AU2017230658B2 (es) |
| CA (1) | CA3016096C (es) |
| IL (1) | IL261559B (es) |
| PE (1) | PE20181894A1 (es) |
| WO (1) | WO2017153186A1 (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI791251B (zh) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| UA123637C2 (uk) | 2016-03-10 | 2021-05-05 | Янссен Фармацевтика Нв | Заміщені аналоги нуклеозидів для застосування як інгібіторів prmt5 |
| EP3519413A1 (en) | 2016-10-03 | 2019-08-07 | Janssen Pharmaceutica NV | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| BR112019017466A2 (pt) | 2017-02-27 | 2020-03-31 | Janssen Pharmaceutica Nv | Uso de biomarcadores na identificação de pacientes com câncer que serão responsivos a tratamento com um inibidor de prmt5 |
| UA126481C2 (uk) | 2017-08-09 | 2022-10-12 | Прел'Юд Терап'Ютікс, Інкорпорейтід | Селективний інгібітор протеїнової аргінінметилтрансферази 5 (prmt5) |
| WO2019084470A1 (en) * | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
| AU2018372211B2 (en) | 2017-11-24 | 2023-02-02 | Jubilant Episcribe LLC, | Heterocyclic compounds as PRMT5 inhibitors |
| AU2018381004B2 (en) * | 2017-12-05 | 2021-04-29 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as PRMT5 inhibitors |
| IL275129B2 (en) * | 2017-12-08 | 2023-10-01 | Janssen Pharmaceutica Nv | Novel spirobicyclic analogues |
| IL277263B2 (en) | 2018-03-14 | 2024-07-01 | Prelude Therapeutics Inc | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| US20210309687A1 (en) * | 2018-08-07 | 2021-10-07 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| CN109400545B (zh) * | 2018-12-24 | 2022-03-25 | 济南大学 | 一种精氨酸甲基转移酶5抑制剂及其应用 |
| KR20210105955A (ko) * | 2019-01-23 | 2021-08-27 | 화이자 인코포레이티드 | 공지된 테트라히드로이소퀴놀린 유도체의 모노포스페이트 수화물 염의 다형체 형태 |
| WO2020198323A1 (en) * | 2019-03-25 | 2020-10-01 | California Institute Of Technology | Prmt5 inhibitors and uses thereof |
| US11198699B2 (en) | 2019-04-02 | 2021-12-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| EP3946352B1 (en) | 2019-04-05 | 2025-12-31 | Prelude Therapeutics Incorporated | SELECTIVE INHIBITORS OF ARGININE PROTEIN METHYLTRANSFERASE 5 |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| MX2021015363A (es) | 2019-06-12 | 2022-04-06 | Janssen Pharmaceutica Nv | Intermedios espirobicíclicos novedosos. |
| WO2021055797A1 (en) * | 2019-09-18 | 2021-03-25 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| JP7429799B2 (ja) | 2020-02-18 | 2024-02-08 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス化合物 |
| CN111233869B (zh) * | 2020-03-12 | 2022-09-16 | 杭州新博思生物医药有限公司 | 用于制备瑞德西韦关键中间体的新化合物及其制备方法 |
| CN113527303B (zh) * | 2020-04-21 | 2022-06-10 | 浙江工业大学 | 一种瑞德西韦母核中间体的制备工艺 |
| EP4229067A1 (en) * | 2020-10-14 | 2023-08-23 | Accent Therapeutics, Inc. | Mettl3 modulators |
| US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| KR20240049311A (ko) | 2021-08-18 | 2024-04-16 | 길리애드 사이언시즈, 인코포레이티드 | 인지질 화합물 및 이의 제조 및 사용 방법 |
| CN114573590B (zh) * | 2022-03-18 | 2023-11-14 | 苏州旺山旺水生物医药有限公司 | 一种四异丁酰基核苷类似物的制备方法及用途 |
| WO2024073709A2 (en) * | 2022-09-30 | 2024-04-04 | Alnylam Pharmaceuticals, Inc. | Modified oligonucleotides and double-stranded rnas |
| CN115745998B (zh) * | 2022-11-07 | 2024-10-22 | 新乡学院 | 光催化合成水粉蕈素及其类似物的方法 |
| CN116003339B (zh) * | 2022-12-01 | 2024-06-28 | 南京师范大学 | 一种巨噬细胞迁移抑制因子mif双光子荧光探针及其制备方法和应用 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530207A (zh) * | 2023-08-16 | 2025-08-01 | 智擎生技製藥股份有限公司 | Ｍｔａ協同性的ｐｒｍｔ５抑制劑 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026008533A1 (en) | 2024-07-01 | 2026-01-08 | Janssen Pharmaceutica Nv | Prmt5 inhibitors for treating adenomas |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224438A (en) * | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| GB2043371B (en) | 1979-02-21 | 1983-05-25 | South Eastern Elec Board | Load shedding |
| US7034147B2 (en) * | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| PL372145A1 (en) | 2002-02-19 | 2005-07-11 | Cv Therapeutics, Inc. | Partial and full agonists of a sb 1 /sb adenosine receptors |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| AU2011341441A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| WO2014100730A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| WO2014100695A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| SI2935222T1 (sl) | 2012-12-21 | 2019-02-28 | Epizyme Inc. | Inhibitorji PRMT5 in njihove uporabe |
| EA031895B1 (ru) | 2015-02-24 | 2019-03-29 | Пфайзер Инк. | Замещенные нуклеозидные производные, полезные в качестве агентов против рака |
-
2017
- 2017-02-24 CN CN201780016075.0A patent/CN108884108B/zh active Active
- 2017-02-24 CA CA3016096A patent/CA3016096C/en active Active
- 2017-02-24 WO PCT/EP2017/054324 patent/WO2017153186A1/en not_active Ceased
- 2017-02-24 EP EP17706513.3A patent/EP3426664B1/en active Active
- 2017-02-24 PE PE2018001785A patent/PE20181894A1/es unknown
- 2017-02-24 KR KR1020187026088A patent/KR20180116307A/ko active Pending
- 2017-02-24 AU AU2017230658A patent/AU2017230658B2/en active Active
-
2018
- 2018-09-03 IL IL261559A patent/IL261559B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017230658B2 (en) | 2021-03-04 |
| WO2017153186A1 (en) | 2017-09-14 |
| EP3426664A1 (en) | 2019-01-16 |
| CA3016096A1 (en) | 2017-09-14 |
| CA3016096C (en) | 2023-10-17 |
| KR20180116307A (ko) | 2018-10-24 |
| IL261559A (en) | 2018-10-31 |
| AU2017230658A1 (en) | 2018-08-30 |
| EP3426664B1 (en) | 2021-06-30 |
| CN108884108A (zh) | 2018-11-23 |
| IL261559B (en) | 2021-09-30 |
| CN108884108B (zh) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181894A1 (es) | Nuevos analogos de nucleosidos sustituidos para su uso como inhibidores de prmt 5 | |
| MX2019011693A (es) | Compuestos que inhiben la proteina mcl-1. | |
| CL2020002198A1 (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20221629A1 (es) | Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5 | |
| BR112016011949A8 (pt) | composto, composição farmacêutica, e, uso dos mesmos | |
| AR098048A1 (es) | Inhibidores de fgfr4 | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| AR071717A1 (es) | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| PE20190111A1 (es) | Nuevos derivados aminoacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| UY30298A1 (es) | Inhibidores de la quinasa c-fms ii | |
| CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| BR112016028818A2 (pt) | composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo. | |
| CL2017000271A1 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| PE20190706A1 (es) | Analogos novedosos de carbanucleosidos sustituidos de sistema anular monociclico y bicicilo para su uso como inhibidores de prmt5 |